Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 18/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL5608824 | 0.98 | FDPS (0.70) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL429804 | 0.96 | FDPS (0.79) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7831396 | 0.94 | FDPS (0.76) | FDPSPDE3ALMNAADRB3PDE4D | |
| Neridronic Acid SCHEMBL10607521 | 0.89 | FDPS (0.75) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7744621 | 0.88 | FDPS (0.92) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4270336 | 0.88 | FDPS (0.87) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4279500 | 0.87 | FDPS (0.64) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7751945 | 0.86 | FDPS (0.89) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7749180 | 0.86 | FDPS (0.89) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4279503 | 0.86 | FDPS (0.83) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758594-A1 | COMBINATION FOR INHIBITING BONE RESORPTION COMPRISING A BISPHOSPONATE (ALENDRONA) AND A VITAMIN D (CHOLECALCIFEROL) | Merck and Co., Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005117906-A1 | COMBINATION FOR INHIBITING BONE RESORPTION COMPRISING A BISPHOSPONATE (ALENDRONA) AND A VITAMIN D (CHOLECALCIFEROL) | MERCK & CO., INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050261250-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC., | 2005-11-24 | — | — | US | disclosed |
| US-20050176685-A1 | Method for inhibiting bone resorption with an alendronate and vitamin d formulation | DAIFOTIS ANASTASIA G (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1494683-A1 | METHOD FOR INHIBITING BONE RESORPTION WITH AN ALENDRONATE AND VITAMIN D FORMULATION | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1458400-A1 | LIQUID BISPHOSPHONATE FORMULATIONS FOR BONE DISORDERS | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003086415-A1 | METHOD FOR INHIBITING BONE RESORPTION WITH AN ALENDRONATE AND VITAMIN D FORMULATION | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195171-A1 | Method for inhibiting bone resorption with an alendronate and vitamin D formulation | DAIFOTIS ANASTASIA G (US) | 2003-10-16 | — | — | US | disclosed |
| US-20030139378-A1 | Liquid bisphosphonate formulations for bone disorders | DAIFOTIS ANASTASIA G (US) | 2003-07-24 | — | — | US | disclosed |
| WO-2003051373-A1 | LIQUID BISPHOSPHONATE FORMULATIONS FOR BONE DISORDERS | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195171-A1 | Method for inhibiting bone resorption with an alendronate and vitamin D formulation | CYP24A1, PTH1R, VDR | FDPS 1094/4885PDE3A 2307/4885LMNA 3150/4885 |
| US-20050261250-A1 | Compositions and methods for inhibiting bone resorption | PTH1R, CYP24A1, VDR | FDPS 632/4885PDE3A 1161/4885LMNA 2307/4885 |
| US-20050176685-A1 | Method for inhibiting bone resorption with an alendronate and vitamin d formulation | CYP24A1, VDR, PTH1R | FDPS 1234/4885PDE3A 2572/4885LMNA 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.